 METHADONE MAINTENANCE TREATMENT *Methadone Maintenance Treatment Is The Most Effective Treatment for Opiate Addiction*
Methadone is a synthetic agent that works by "occupying" the brain receptor sites affected by heroin and other opiates. Methadone: • blocks the euphoric and sedating effects of opiates; • relieves the craving for opiates that is a major factor in relapse; • relieves symptoms associated with withdrawal from opiates; • does not cause euphoria or intoxication itself (which allows a person to work and participate normally in society;) • is excreted slowly so it can be taken only once a day. Methadone maintenance treatment, a program in which addicted individuals receive daily doses of methadone, was initially developed during the 1960s as part of a broad, multicomponent treatment program that also emphasized resocialization and vocational training. *Methadone Maintenance Treatment has Important Benefits for BOTH Addicted Individuals and for Society.* Key Issues in Effective Methadone Maintenance Treatment Dose Most patients require a dose of 60-120 mg/day to achieve optimum therapeutic effects of methadone. Compared to those on lower doses, patients on higher doses are shown to stay in treatment longer, use less heroin/opioids, and have lower incidence of HIV infection. Some patients need even higher doses for fully effective treatment. Studies of methadone effectiveness have shown a dose-response relationship, with higher doses more effective in reducing heroin use, helping patients stay in treatment, and reducing criminal activity. Despite compelling evidence that doses need to be determined on an individual basis, that higher doses are more effective, and that doses of 60-120 mg/day are required for most patients, some clinics administer fixed doses to all patients and provide less than optimal doses. Current Changes In May 2001, the U.S. Department of Health and Human Services (DHHS) announced a new system for regulating and monitoring MMT. Under this new system, oversight responsibility for MMT in the United States shifted from the Food and Drug Administration (FDA) to the Substance Abuse and Mental Health Services Administration’s Center for Substance Abuse Treatment (CSAT). This new system represents a fundamental change in the approach to substance abuse treatment and in the federal government’s role in ensuring effective and accountable MMT programs. It relies on accreditation of MMT programs by independent organizations and states, in accordance with treatment standards that have been developed by CSAT over the last 10 years. These standards reflect current knowledge about the nature of opiate addiction as a chronic brain disease and the principles underlying effective long-term, comprehensive treatment. Know Your Rights! If You are currently a MMT patient and YOUR RIGHTS are being violated, there are people who will listen! Go To : http://www.methadone.org/grievance_report.html  |
Methadone Regulations :
|
e of National Drug Control Policy:
| |||||||||||||
|
|
"Proper use of methadone is sometimes appropriate for certain individuals in recovery. SAMHSA’s guidelines, include
Follow Directions: How to Use Methadone Safely, outlines the risks, considerations, and precautions of taking the medication.
Methadone clinics are functional medical facilities where staff members work to assist patients with rehabilitation and first steps on the road to recovery. In some cases, these clinics may be the appropriate choice for those in early recovery. In other instances, different types of addiction recovery programs may better serve Regardless of the type of treatment chosen, comprehensive care is always needed. " (samhsa, 2015).
| methadone_safety_overview.pdf |
| history_of_methadone.pdf |
| the_brain_and_addiction.pdf |
| dole_nyswander_1967.pdf |
| opioid_treatmnt_prog_overview.pdf |
American Association for Treatment
of Opioid Dependence
AATOD has been increasingly concerned about the impact of prescription opioid use has had upon admissions to MMT (methadone maintenance treatment) programs.
Over the course of the past several years, we have received anecdotal reports from State Methadone Authorities, county governments and methadone treatment programs with regard to the admission of patients, suffering from long-term prescription opioid addiction.
AATOD has developed a research project through a grant from Purdue Pharma. This three-year Opioid Use Study, which will involve 75 treatment programs, representing all of the regions in the United States, will be the first longitudinal trend analysis to evaluate the prevalence of prescription opioid abuse among new admissions to methadone treatment programs. Each of the participating programs will provide an anonymous survey instrument to every patient being admitted into the program.
The information collected from the survey instrument will be analyzed independently by the National Development and Research Institute (NDRI) a leading and a nationally recognized research based organization. All of the survey data will be forwarded to NDRI to ensure complete independence of survey data collection and analysis. NDRI will track these data on a quarterly basis and will be responsible for publishing all such information in making presentations at national and international conferences.
Project Update
AATOD began collecting data from 71 programs in 32 states, beginning on January 2, 2005 following
field testing in five treatment settings. Each of the participating programs provided a survey to patients being admitted to the program and each patient made a voluntary decision to participate by completing the survey questionnaire.
We collected 7,435 patient surveys from the participating OTPs between January -December 11, 2005. Seventy-one programs were actively involved in submitting information to NDRI, representing 32 states in every region of the United States.
We have already learned a tremendous amount of information from this study. Some of the critical early findings of this past year have been that 71% of the reporting patients are Caucasian. Additionally, 46% of the patients indicated employment as their primary source of income.
Approximately 2,500 of the 7,400 patients were in the age range of 18-29, representing a younger population entering treatment.
Equally significant, 38% of patients reported having moderate to severe chronic pain. 35% of the patients reported bodily pain as a reason for enrollment in methadone treatment programs.
We also learned that 78% of the patients injected heroin as their primary drug of abuse, while 35% were injecting prescription opioids.
We will continue to collect information from a greater number of programs in 2006, bringing the total number of reporting programs to 75. We anticipate another 7,500-8,000 patients to be involved in this study as well.
American Association for the Treatment
of Opioid Dependence (AATOD)
217 Broadway, Suite 304
New York, NY 10007
Ph: 212.566.5555 Fax: 212.349.2944
Email: [email protected]
L O C A L C L I N I C S
 |
~CLICK ON ARROW BELOW TO WATCH VIDEO~
*NEW OTP Standards as of 02/2010 (OASAS NYS)*
Section 828.11: Medication administration
(h) A patient's approved medication shall not be withheld to enforce patient compliance with clinic rules
or procedures, including but not limited to, rules on submitting to toxicology tests.
QUESTION: Does this also pertain to take out medication or just daily dose? If a patient has a pickup schedule based on employment and fails to provide proof of employment by a certain, agreed upon date, can the program refuse to provide take out medication and be in compliance with this regulation?
ANSWER:. This section is referring to patient’s observed daily dose at the window, which can only be delayed, reduced or not administered for an emergent medical reason. This was added to the new regulations because in the past programs have abused withholding a patient’s medication for many non-medical reasons.
GET EDUCATED - For Yourself, For The Next Person Seeking Help.
>To Print this document to provide to your clinic DOWNLOAD below.
| faq828.pdf |
Organizations & Websites To Learn More About Methadone
 ~ Methadone Anonymous ~
|
www.MethadoneSupport.org
 <><><><><><><><><>
|
D o Y o u K n o w ?
*THE IMPORTANCE OF DR. VINCENT DOLE & DR MARIE NYSWANDER*
 DR VINCENT DOLE & DR MARIE NYSWANDER so jUst wHo iS tHiS
|
The FIRST Study
| ||
COMING SOON:
TO FIND A CLINIC NEAREST YOU EMAIL ME AT : [email protected]
OR
Click On Link Below To Lookup Your Area
Opioid Treatment Program Directory
Link to view the opioid treatment programs in your State:
http://dpt2.samhsa.gov/treatment/
**SITE STILL UNDER CONSTRUCTION: CHECK BACK FREQUENTLY FOR MORE ADDITIONS**
*LINKS TO ONLINE ARTICLES/NEWS COVERING ADDICTION/METHADONE TREATMENT*
In Some States, More Die from Drugs than Car Crashes, CDC Says
October 1, 2009
*Rising rates of prescription-drug overdoses have propelled drug-related fatalities to the top of the accidental-death list in a growing number of states, according to a new report.
LINK: http://www.jointogether.org/news/research/summaries/2009/in-some-states-more-die-from.html
October 1, 2009
*Rising rates of prescription-drug overdoses have propelled drug-related fatalities to the top of the accidental-death list in a growing number of states, according to a new report.
LINK: http://www.jointogether.org/news/research/summaries/2009/in-some-states-more-die-from.html
Disclaimer: The contents of OpioidAddiction.weebly.com/HALO inc. are for general informational purposes only and are not intended to substitute for professional or medical evaluation, diagnosis, treatment, or advice. Users of this site are encouraged to contact your professional healthcare provider for medical assistance regarding addictive disorders, general health problems, mental health problems, and any & all health-related questions.
